UI Hospitals and Clinics

Clinical Research Studies



Age Group

More options for age range


Clinical Research started within last


Principal Investigator

Showing 1 - 5 of 149 results
Page 1 of 30   

Ketogenic Diet

Principal Investigator
Sudershan Bhatia, MD
Department or Field of Study

Participants in this research study have been diagnosed with pancreatic cancer and recommended for chemotherapy and radiation therapy by their doctor. The purpose of the study is to determine the effects, good and bad, of subject's participation in a special ketogenic diet, with very low level of carbohydrates (sugars), during chemotherapy and radiation therapy for pancreatic cancer. Animal research suggests that lower blood sugars increase treatment effect. That is why we are doing research on this special diet.

age group:18 to 99 years trial start date:June 3, 2011
Gender Preference:none Trial End Date: June 3, 2021
Contact Info:


Keywords: bhatia ; cancer ; ketogenic diet ; pancreatic cancer ; phase 1 ; phase I

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)

Principal Investigator
Benjamin Miller MD

Participants in this study are undergoing tumor resections with endoprosthetic replacements. Limb salvage surgery is the standard of care in the management of sarcoma of the long-bones. Advances in chemotherapeutic regimens and imaging techniques allow for wide resection and functional reconstruction in the 95% of patients. The most common type of long-bone reconstruction involves the use of a tumor prosthesis, or endoprostheses. Due to the complexity and length of surgical resection and reconstruction, as well as the immunocompromised nature of patients treated with chemotherapy, the risk for infection remains high. The purpose of this study is to investigate whether a long term (5 days) postoperative antibiotic regimen will decrease the rate of infection among patients being surgically treated for a lower extremity bone tumor when compared to a short term (24 hours) postoperative antibiotic regimen. About 1000 participants will take part in this study at centers around the country; approximately 20 participants will take part in this study at the University of Iowa.

age group:0 to 99 years trial start date:May 6, 2014
Gender Preference:none Trial End Date: December 1, 2015
Contact Info:

Nancy McCurdy      319-356-8699

Keywords: Cancer ; Endoprosthetic ; Miller ; Tumor

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

Principal Investigator
Alexandra Thomas, MD

Participants in this research study have breast cancer that is HER2-positive and is sensitive to hormones. The purpose of this research study is to compare the good and bad effects of using hormone drugs with the usual chemotherapy drugs to using the chemotherapy drugs alone as therapy given before surgery.

Approximately 7 people will take part in this treatment study conducted by investigators at the University of Iowa. There will be about 212 people taking part in this study nationally.

age group:18 to 99 years trial start date:May 2, 2014
Gender Preference:female Trial End Date: January 1, 2017
Contact Info:

Pamela Zehr      319-353-8914

Keywords: Enter keyword

Exelixis METEOR 2nd line Cabozantinib (XL184) vs Everolimus in RCC

Principal Investigator
Daniel Vaena, MD

Participants in this study are diagnosed with renal cell cancer (RCC). The purpose of this study is to evaluate the effect of study drug cabozantinib compared with everolimus on overall survival (OS) and progression-free survival (PFS) in subjects with advanced RCC. This study will be take place at approximately 200 global clinical sites with a total of about 650 participants. Approximately 9 participants will take part in this study at the University of Iowa.

age group:18 to 99 years trial start date:May 9, 2014
Gender Preference:none Trial End Date: May 1, 2015
Contact Info:

Julie Schlabaugh      Julie-Schlabaugh@uiowa.edu

Keywords: Cabozantinib ; Cancer ; Everolimus ; Phase 3 ; Phase III ; Renal Cell ; Vaena


Principal Investigator
Gary L. Pierce, PhD
Department of Health and Human Physiology

Research Study to Investigate the Effects of a Common Anti-inflammatory Drug on Blood Vessel and Heart Function

Healthy, non-smoking adults age 50-79 years are invited to participate in a research study to test the effects of the drug salsalate (similar to aspirin) to test blood vessel and heart function.  Your involvement will include; blood draws, 24 hour blood pressure monitoring, surveys, and tests of blood vessel function.  Compensation will be provided.  For details, please contact Veronica Howsare (319) 467-5677 or email veronica-howsare@uiowa.edu.

 The lead investigator at the University of Iowa is Gary L. Pierce, PhD, Assistant Professor, Health Human Physiology.

age group:50 to 79 years trial start date:August 8, 2012
Gender Preference:none Trial End Date: February 20, 2015
Contact Info:

Veronica Howsare: (319) 467-5677


Keywords: Anti-Inflammatory Drug ; Blood Vessel Function ; Heart Function
Page 1 of 30
« 1 2 3 4 5  ... » 
Results per page

Clinical Research Studies


Your Selections

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.